Amerikaanse aandelen Terug naar discussie overzicht

GNBT

1. [verwijderd] 14 december 2009 22:12

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   
   
   (Source: Business Wire)trackingMentor Capital, Inc.'s (Pink Sheets:MNTR) proprietary Cancer Immunotherapy Index has appreciated at a 100% annualized rate since its creation by Mentor Capital, July 10, 2009. In response to the resulting investor interest, Mentor Capital plans to initiate an actively managed Cancer Immunotherapy Index fund in January 2010. A significant majority of Mentor Capital cash proceeds that spring from its $140 million in freely tradable warrants are targeted to be invested through the fund.
   
   Investment across the Cancer Immunotherapy Index will broaden Mentor Capital's already significant immunotherapy investment interest in CI Index member Quantum Immunologics, Inc., a private company in FDA authorized breast cancer trials. Other Cancer Immunotherapy Index companies are: Dendreon (NASDAQ:DNDN), Oncothyreon (NASDAQ:ONTY), ImmunoCellular Theraputics (OTCBB:IMUC), Antigenics (NASDAQ:AGEN), Biovest International (BVTI.PK), Celldex Therapeutics (NASDAQ:CLDX), Northwest Biotherapeutics (OTCBB:NWBO), CEL -- SCI Corp. (AMEX:CVM) and Generex Biotechnology (NASDAQ:GNBT) as a proxy for its wholly owned immunotherapeutic subsidiary, Antigen Express. As other companies are brought into the CI Index, Mentor Capital will take an investment position in them with specific weighting based on the evaluation of their medical promise.
   
   $1.2 million in initial seed funding for the CI Index will be provided approximately one-third each by Mentor Capital management, WellCap Partners who will administer the fund under Mentor Capital direction, and Mentor Capital warrant holders. To allow for the Mentor Capital warrant holder funding, their Mentor Capital Series C warrants are set to $0.65 and called by this notice, subject to redemption on February 1, 2010.
   
   In cancer immunotherapy, instead of chemotherapy, surgeries and radiation, the body's own immune system is triggered to attack cancer cells. The USA market addressed by the Cancer Immunotherapy Index companies is estimated at $45 billion. The current combined market cap of the index component companies is $3.4 billion.
   
   Regular detail updates of the Cancer Immunotherapy Index and additional company information may be reviewed at www.MentorCapital.com.
   
   Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.
   
   A service of YellowBrix, Inc.
   
2. [verwijderd] 14 december 2009 22:14

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Another big gainer was small-cap Generex Biotechnology Corp. /quotes/comstock/15*!gnbt/quotes/nls/gnbt (GNBT 0.64, +0.08, +14.31%) , shares of which jumped 8% to 60 cents.
   
   Generex reported favorable Phase II data for its new vaccine to help prevent the recurrence of certain types of breast cancer.
   
   Generex shares have been on a roll since last week, when the company signed a manufacturing deal for Oral-lyn, its orally administered insulin product, with pharmaceutical giant Sanofi-Aventis /quotes/comstock/13*!sny/quotes/nls/sny (SNY 38.74, -0.02, -0.06%) .
   
   Val Brickates Kennedy is a reporter for MarketWatch in Boston.
3. [verwijderd] 14 december 2009 22:16

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Generex Presents Encouraging Interim Results of Phase II Breast Cancer Study
   Globe Newswire
   Novel Immunotherapeutic Breast Cancer Vaccine on Track for Demonstration of Efficacy
   December 14, 2009: 09:30 AM ET
   
   WORCESTER, Mass., Dec. 14, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) today announced presentation of interim results from a Phase II efficacy study of a novel immunotherapeutic vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The results were presented at the 32nd Annual San Antonio Breast Cancer Symposium (www.sabcs.org). The trial is being conducted by COL George Peoples, MD, a collaborator of Antigen Express working at the Brooke Army Medical Center.
   
   The presentation, entitled Interim analysis of a randomized phase II study of the novel Ii-Key hybrid HER2/neu peptide (AE37) vaccine to prevent breast cancer recurrence: United States Military Cancer Institute Clinical Trials Group Study I-05, showed that only half the number of patients in the treatment arm of the study relapsed compared to those not receiving the vaccine. The trial is a fully randomized and controlled study examining the rate of relapse in patients diagnosed with node-positive or high risk node negative breast cancer. The final endpoint will examine the relapse rate after two years; the results presented at the conference were those observed in patients 13.5 months after treatment.
   
   Antigen Express, Generex's immunotherapy division, is developing novel synthetic peptide vaccines for potent and specific stimulation of CD4+ T helper cells. The vaccine being studied in this trial, AE37, was shown to be safe, well-tolerated and produced the desired immunological activity in both a Phase I trial in breast cancer patients and a Phase I trial in patients with prostate cancer. AE37 is also the subject of an additional Phase I clinical trial in patients with breast or ovarian cancer in which it is being combined with another immunotherapeutic peptide.
   
   In addition to cancer, the proprietary Antigen Express technology is being applied to vaccine development for infectious diseases. In particular, a synthetic peptide vaccine is currently being developed for the H1N1 swine flu virus.
   
   About Generex Biotechnology Corporation
   
   Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
   
   The Generex Biotechnology Corp. logo is available at www.globenewswire.com/newsroom/prs/?p...
   
   Safe Harbor Statement
   
   This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
   
   CONTACT: American Capital Ventures, Inc.
   Investor Relations Contact:
   Howard Gostfrand
   1-877-918-0774
   
   Beckerman Public Relations
   Media Contact:
   Angelene Taccini
   201-465-8024
   
   Generex Biotechnology Corp. Logo
4. [verwijderd] 24 december 2009 05:07

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   
   Generex Biotechnology's EBITDA Hits Eleven Year Low
   12/23/2009
   
   New York, NY, December 23, 2009-Ebitda News reports that negative EBITDA for Generex Biotechnology Corporation (NASDAQ:GNBT) for its quarter ended October 31, 2009 was $(7,981,731), a 154% deterioration over the year earlier same quarter when Generex Biotechnology generated $(3,144,848) in negative EBITDA. Generex Biotechnology has generated nine consecutive quarters of negative EBITDA. EBITDA for the most recent quarter also reached a eleven year low.
   
   For Generex Biotechnology's twelve months ended October 31, 2009 EBITDA was $(13,638,062), compared with $(24,416,867), a 44% improvement over the comparable year earlier twelve months. EBITDA for the most recent twelve months also reached a two year high.
   
   The shares of Generex Biotechnology were recently trading at $0.57.
   
   EBITDA defined by Ebitda News:
   
   EBITDA is an acronym for (Earnings Before Interest Taxes Depreciation & Amortization) and it is calculated by taking Operating Income and adding or subtracting depreciation and/or amortization.
   
   EBITDA is a relatively new performance metric that came into vogue during the 1980s.
   The reason why is because corporations in the 1980s significantly increased the use of debt to finance their operations and acquisitions. Many investors and analysts believe that the increased interest expense as a percentage of total income due to the significant increase in debt masks the performance of an operating business and thus reduces the valuation of that business when traditional valuation metrics such as after tax income are utilized. EBITDA was created so that investors and analysts would be able to understand a company’s cash earnings power before non-cash items such as depreciation and amortization and interest and taxes were expensed. EBITDA has also become an increasingly popular performance measure for global investors and analysts because many countries have varying corporate tax rates. The simple theory behind EBITDA is that it is the actual profit that a business or corporation would generate if it were to be sold to an all cash buyer.
   
   Ebitda News is currently the only "EBITDA" news source for over 8,000 public companies for monitoring and reporting on EBITDA. It currently publishes over 30,000 stories per year related to EBITDA and is the leading global source for EBITDA related news. Ebitda News’s company, industry, indices, sector and ETF news and archives are available at www.StockTrendNews.com.
   
   www.stocktrendnews.com/index.php?fuse...
   
   Skip
   
5. [verwijderd] 5 januari 2010 19:50

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   vandaag behoorlijk omhoog (+10%) Iemand een id waarom ?
   
   
6. welshterrier 5 5 januari 2010 20:24

   auteur info

   • welshterrier 5

     Lid sinds: 23 mrt 2004

     Laatste bezoek: 08 apr 2025

   • Aanbevelingen

     Ontvangen: 291

     Gegeven: 1101

   •    Aantal posts: 20.113

   denk dat Sky wat heeft bijgekocht :-)))
7. [verwijderd] 5 januari 2010 20:30

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   welshterrier schreef:

   denk dat Sky wat heeft bijgekocht :-)))
   

   hahahaha
   een abtje voor mevrouw welsh ;-)))
   
   oepssss nu zijn we straks weer een target.... :S
   
   :X
8. gustaaf1e 5 januari 2010 22:23

   auteur info

   • gustaaf1e

     Lid sinds: 01 jan 2000

     Laatste bezoek: 14 apr 2025

   • Aanbevelingen

     Ontvangen: 54

     Gegeven: 1

   •    Aantal posts: 1.656

   waarom?
   zie website van Generex met verwijzing naar artikel/interview over ontwikkeling van borstkankermedicijn.
   G
9. [verwijderd] 5 januari 2010 22:44

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   1gustaaf schreef:

   waarom?
   zie website van Generex met verwijzing naar artikel/interview over ontwikkeling van borstkankermedicijn.
   G
   

   Heeft 'vandaag' hier met te maken:
   UPDATE 1-MannKind CEO says discussing Afresa label with FDA.
   * CEO says FDA ruling on Afresa may be delayed
   www.reuters.com/article/idUSN05104180...
   
   Eventueel een 'competitor' minder!!?
10. [verwijderd] 11 januari 2010 15:23

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    pre 0.73
    
    meneer sky weer helemaal happy vandaag ;-))
    
    Major U.S. Pharmacy Chain to Market Generex's Crave-NX(TM) 7-Day Diet Aid Spray Throughout Its Nationwide Network of Over 7,000 Stores
    Globe Newswire
    Generex to Support January 2010 Store Launch With Focused TV, Radio and Print Advertising Campaign
    January 11, 2010: 09:00 AM ET
    
    money.cnn.com/news/newsfeeds/articles...
    
    WORCESTER, Mass., Jan. 11, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has reached an agreement with a major nationwide pharmacy chain to market the Company's proprietary Crave-NX(TM) 7-Day Diet Aid Spray (www.Crave-NX.com) throughout the pharmacy's nationwide network of over 7,000 stores beginning in January 2010.
    
    Crave-NX(TM) 7-Day Diet Aid Spray is a great tasting orange-flavored formulation sprayed into the mouth, scientifically formulated to quickly curb cravings throughout the day, saving valuable calories. According to Marketdata Enterprises, Inc. (www.marketdataenterprises.com), a leading market research publisher of service industry studies, the total U.S. weight loss market generated sales of $59 billion in 2007. It is estimated that 72 million people are dieters with approximately 70% of those dieters attempting lose weight without professional help.
    
    The Crave-NX(TM) 7-Day Diet Aid Spray to be carried on the shelves of this leading nationwide pharmacy chain has been clinically-tested, has 20 servings per bottle, with only two calories per serving and zero fat. Crave-NX(TM) is a brand new diet aid that can help "Spray the Crave Away(TM)" while saving calories by controlling the user's sweet tooth and junk food cravings throughout the day, which can save up to 1,000 calories per day. Over a one-year period, saving just 250 calories per day adds up to over 90,000 calories -- or 26 pounds. Both companies intend to position Crave-NX as a product to complement other diet products and/or programs that help provide incremental sales for the pharmacy retailer and a new diet add-on solution for the consumer.
    
    Commenting on the event Bill Abajian, Sr. Executive Advisor of Global Licensing and Business Development for Generex, stated "The launching of CraveNx(TM) 7-Day Diet Spray with this major pharmacy chain in North America is a significant step forward for Generex as it enters its commercialization phase and a key part of our global marketing strategy. Not only will this make our product widely available to consumers across the U.S., it also adds significant credibility for us as we roll out this brand. We formulated CraveNx(TM) 7-Day Diet Spray to act as a useful tool to combat those late-morning and late afternoon snack cravings that lead to excessive calorie intake as well as obesity and we are fully prepared to support the pharmacy's sales efforts. We have an aggressive media campaign consisting of TV, radio and print ads to create market awareness on the benefits of this product to coincide with the launch."
    
    Generex has recently begun a new media campaign with radio ads already airing in New York, New Jersey, Houston, and Dallas, and is also expanding into television ads in these same markets. The radio and television ads can be heard and viewed at www.barkerdzp.com/cravenx/.
12. [verwijderd] 11 januari 2010 15:24

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    en de high 0.89 zie ik...
13. welshterrier 5 11 januari 2010 15:27

    auteur info

    • welshterrier 5

      Lid sinds: 23 mrt 2004

      Laatste bezoek: 08 apr 2025

    • Aanbevelingen

      Ontvangen: 291

      Gegeven: 1101

    •    Aantal posts: 20.113

    quote:

    roos1971 schreef:

    en de high 0.89 zie ik...
    

    een dieet spray, lijkt me wel wat
14. [verwijderd] 11 januari 2010 15:29

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    welshterrier schreef:

    [quote=roos1971]
    en de high 0.89 zie ik...
    [/quote]
    
    een dieet spray, lijkt me wel wat
    

    gaan we doen!! beter dan zweten of neit dan ;-))
    
    
15. [verwijderd] 11 januari 2010 23:02

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    lekkere stijging vandaag. Morgen weer ?
    
    
16. [verwijderd] 14 januari 2010 19:41

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    
    Reuters Rates Generex “Outperform”.
    www.stockcast.info/images/fbfiles/fil...
17. [verwijderd] 1 februari 2010 12:44

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Home
    Advice
    Alerts
    FDA Updates
    Alternative Energy
    Conferences
    Daily Profiles
    Mid and Large Cap
    Small and Micro Cap
    Featured
    Humour
    Promotions
    Videos
    World News
    International Markets
    US Markets
    Highly Bullish Technical Trading Alert Issued for Generex, Golden Cross Imminent
    Written by Michael Vlaicu Alerts Feb 1, 2010
    vote
    nowBuzz up!
    A highly bullish technical trade alert has been issued on Generex Biotechnology Corporation (NASDAQ:GNBT) on the even of the N.I.C.E. conference news. The company was recently introduced on our website as one of the most undervalued biotechnology companies of the early 2010 year, keeping investors glued to the screen as they await any new developments. Within the next few days, the company should release a handful of key updates, which could potentially propel the stock’s price to retest the 0.7 resistance
    
    Taking a look at the chart, it is easy to see why technical analysis fans might call this a ‘lucky break’ type of investment, and there’s a number of reasons to validate that terminology. Firstly, the all important Relative Strength Index (RSI) has positioned itself in an upward trend, making a move past the climactic 49.79 level, representing that the stock has a neither overbought or oversold sentiment in the market. Next in line we have the MACD divergence which is beginning to turn and trend upward, followed by the Full Stochastics which is bouncing off the key 18.50 bottom further verifying the bullish indicators. Most importantly, we notice the volume bars marked by the green, and the red bars which represent the sell orders. As we can see, the fewer green bars outweigh the many smaller red bars, indicating a long-term bullish pattern, and further confirming that the recent decline was a simple consolidation, perhaps an indication of longs taking profits.
    
    Currently the stock has reached a strong support level at the $0.60 price per share level, which should not be broken, unless some bad news is expected, however, highly unlikely. During the last few days, we noticed the white empty candle sticks which represent the same run-up pattern which cased the stock’s price to rise from $0.50 to $0.70 and beyond. Despite all of this, the most important aspect has yet to be discussed, the Golden Cross. This is the most bullish technical indicator, should it be validated by volume. This occurs when the 50 day Moving Average crosses the 200 day Moving Average while trending upwards. When this occurs in bullish trending stocks 8 times out of 10 times you see the stock gain added momentum as this is a major bullish signal used by technical investors. Long term indicators carry a lot more weight and a Golden Cross indicates a bull market is on the horizon, thus you can expect a lot of stock scanners to showcase Generex as the next big buy signal.
    
    Sign-up for Free to Receive Future Commentary and Trading Alerts on GNBT.
    
    Disclosure: Long GNBT
    
    TheMarketFinancial is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies, unless otherwise stated.
    
    [[T_F]]Data Leak Prevention – Data Security Solutions – Information Theft Protection, Detection and Prevention Software Productstracefusion_signature=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[[T_F]]
    Bookmark & ShareRelated Articles
    Introducing Revolutionary Cancer Immunotherapy While Redefining the Treatment for T1D, T2D (NASDAQ: GNBT)
    Generex Moves Towards Treatments for Diabetes, Cancer (NASDAQ:GNBT
18. [verwijderd] 1 februari 2010 19:30

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    
    (Source: Business Wire)trackingMentor Capital, Inc.'s (Pink Sheets:MNTR) first funding tranche to extend its investment in its proprietary Cancer Immunotherapy Index closes today. Cash investment from 1,400 existing shareholders projects to be approximately 20% oversubscribed from target. Company management reservation to fund will be correspondingly reduced to remain within the $1.2 Million seed funding limit. Already authorized follow-on public funding tranches total an additional $125 Million that will also be targeted for investment into the best of the Cancer Immunotherapy Index companies.
    
    By overweighting the investment of this $125 Million into the most promising Index companies, Mentor Capital seeks to exceed the return of the equally weighted CI Index. The Cancer Immunotherapy Index has grown at an annualized 90% rate since its original creation by Mentor Capital twenty-nine weeks ago.
    
    The current ten CI Index companies that Mentor Capital has invested into are: Dendreon (NASDAQ:DNDN), Immunocellular Therapeutics, Ltd. (OTCBB:IMUC), Oncothyreon (NASDAQ:ONTY), Antigenics (NASDAQ:AGEN), Biovest International (BVTI.PK), Celldex Therapeutics (NASDAQ:CLDX), Northwest Biotherapeutics (OTCBB:NWBO), CEL -- SCI Corp. (AMEX:CVM) and Generex Biotechnology (NASDAQ:GNBT) as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, and Quantum Immunologics, Inc. a private company. In addition to actively managing its investment into these companies, Mentor Capital looks to occasionally add emerging companies to the Index as they reach an adequate size or shift their immunotherapy emphasis from infectious disease to the cancer fight.
    
    Level II trading charts, financial and other information on Mentor Capital, plus listings and links to all Cancer Immunotherapy Index companies may be referenced from the company website: www.MentorCapital.com.
    
    Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.
    
    A service of YellowBrix, Inc.
    
19. [verwijderd] 13 mei 2010 14:38

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    www.thestreet.com/story/10753857/1/ge...
    
    nou meneer sky binnenkort blij? gnbt boven de dollar..
    alleen vervelend bijkomstig feitje zal denk ik zijn dat ie er wel wat minder aandelen aan over houdt...
    
    ze hebben als ik het goed gelezen heb tot begin november om boven de dollar te komen, zodat ze op de nasdaq kunnen blijven.
20. [verwijderd] 17 mei 2010 20:57

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    0,315 inmiddels..
21. welshterrier 5 17 mei 2010 21:06

    auteur info

    • welshterrier 5

      Lid sinds: 23 mrt 2004

      Laatste bezoek: 08 apr 2025

    • Aanbevelingen

      Ontvangen: 291

      Gegeven: 1101

    •    Aantal posts: 20.113

    deze is wel heel breed, sneu voor meneer Sky